Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 26 years of covering Asia Pacific equities, the past 20 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Atlas Arteria (ALX AU): The IE Says NOT Fair & Reasonable. All Eyes On Skyway's Put Option

Atlas Arteria (ALX AU) Stomps On IFM's  "Opportunistic" Offer

Atlas Arteria (ALX AU): IFM's Offer Now Open; Taps Panel Over OTPP's ROFO

Quiddity Advisors

Event-Driven

<ul>
<li>Kroll's "NOT Fair BUT Reasonable" conclusion was subject to scrutiny from the onset given the lower level of its fair value range was just 6% above IFM's top-end Offer price. </li>
<li>After media flagged an expected rebuttal, IFM's supplementary bidder's statement, not surprisingly, flags a "numbers of omissions and unreasonable assumptions" with the Target Statement. </li>
<li>
<a href="https://www.smartkarma.com/entities/atlas-arteria-ltd" target="_blank" data-smartkarma-citation="entities:14430:1" rel="noopener">Atlas Arteria (ALX AU)</a> has now issued a supplementary Target Statement, which appears rushed, and adds little to valuation discussions. </li>
</ul>


Kroll's "NOT Fair BUT Reasonable" conclusion was subject to scrutiny from the onset given the lower level of its fair value range was just 6% above IFM's top-end Offer price. 
After media flagged an expected rebuttal, IFM's supplementary bidder's statement, not surprisingly, flags a "numbers of omissions and unreasonable assumptions" with the Target Statement. 

Atlas Arteria (ALX AU) has now issued a supplementary Target Statement, which appears rushed, and adds little to valuation discussions. 


Atlas Arteria (ALX AU): IFM Advances Offer Benefits & ALX's Tepid Response